In relation to the current standard of care in oncology treatments, KRAS mutations in NSCLC have shown mixed results as predictive clinical biomarkers for survival outcomes with immune checkpoint inhibitor (ICI) treatments [10]. Here, KRAS is linked to non-small cell lung carcinoma.